CD177 and plasma cell myeloma: The most recently approved CART is idecabtagene vicleucel (ide-cell; Abecma), which targets BCMA (B cell maturation antigen), a TNF family cell surface receptor commonly expressed in multiple myeloma, for the treatment of patients with multiple myeloma refractory to or relapsed after at least three prior treatments (147, 148).